9 meters biopharma, inc. (INNT)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Sep'15Jun'15
Net sales

-

-

-

-

-

-

-

-

-

-

-

-

-

1,065

779

1,683

538

4,109

1,334

Cost of goods sold

-

-

-

-

-

-

-

-

-

-

-

-

-

898

687

1,253

491

3,577

1,248

Gross profit (loss)

-

-

-

-

-

-

-

-

-

-

-

-

-

167

92

430

47

532

86

Operating expenses:
Research and development

2,598

5,500

3,943

3,073

1,198

1,743

-1,785

1,243

6,358

1,175

367

1,129

1,335

102

54

65

49

98

119

Selling and marketing

-

-

-

-

-

-

-

-

-

-

-

-

-

649

550

591

635

505

532

General and administrative

1,669

1,838

2,564

3,049

3,114

1,995

1,565

2,132

4,970

1,046

1,973

1,561

2,580

465

1,852

675

992

1,321

492

Warrant inducement expense

690

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

4,959

8,604

6,507

6,123

4,312

3,739

-219

3,376

11,328

2,221

2,340

2,690

3,916

1,216

2,456

1,331

1,676

1,924

1,143

Loss from operations

4,959

8,604

6,507

6,123

4,312

3,739

-219

3,376

11,328

2,221

2,340

2,690

3,916

-1,049

-2,364

-901

-1,629

-1,392

-1,057

Other income (expense):
Interest income

12

28

57

72

26

36

42

54

30

-

-

-

-

-

-

-

-

-

-

Interest income

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

Interest expense

572

494

472

431

427

558

1,038

894

3,661

154

110

99

71

209

25

339

252

75

99

Gain of settlement of customer refund

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

-

Gain (Loss) on Extinguishment of Debt

0

0

0

0

-1,049

0

0

0

0

-

-

-

-

-

-

-

-

-

-

Change in fair value of derivative liability and extinguishment of derivative liability

338

362

229

181

471

50

0

0

0

-

-

-

-

-

-

-

-

-

-

Fair Value Adjustment of Warrants

-1,578

195

2,528

-1,812

-857

0

0

0

0

-

-

-

-

-

-

-

-

-

-

Gain on debt conversion

-

-

-

-

-

-

-

-

-

-

-

-

-

-

557

-

-

0

-

Total other income (expense), net

1,356

-299

-2,713

1,634

-121

-472

-995

-839

-3,631

-154

-110

-99

-71

-

-

-

-

-

-

Total other (income) expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

532

-339

-252

-

-

Debt conversion expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Total other expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-75

-

Total other expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

99

Loss before income taxes

-3,603

-8,904

-9,221

-4,488

-4,434

-4,211

-775

-4,215

-14,959

-2,376

-2,451

-2,790

-3,987

-1,258

-1,832

-1,240

-1,881

-1,467

-1,156

Benefit from income taxes

0

0

0

0

0

0

0

0

0

0

0

0

0

0

2

0

0

1

0

Net Income (Loss) Attributable to Parent

-3,603

-8,904

-9,221

-4,488

-4,434

-4,211

-775

-4,215

-14,959

-2,376

-2,451

-2,790

-3,987

-1,258

-1,834

-1,240

-1,881

-1,468

-1,156

Net loss per common share, basic and diluted (in usd per share)

-0.09

-0.26

-0.26

-0.13

-0.16

-0.09

-0.03

-0.16

-0.70

-0.33

-0.08

-0.23

-0.34

-11.16

-0.27

-0.33

0.50

0.45

0.38

Weighted-average common shares, basic and diluted (in shares)

41,162

36,204

35,883

33,973

27,252

26,291

25,818

25,695

21,243

-7,768

31,545

11,888

11,888

-12,199

6,909

3,750

3,748

3

3